Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Globe Newswire - Dec 18th, 2024

Silo Pharma, Inc., a biopharmaceutical company, announced the initiation of a pharmacokinetic and tolerability study for its novel, non-opioid pain therapeutic, SP-26. The study, conducted in partnership with AmplifyBio, will assess the pharmacokinetics of the dissolvable ketamine-based injectable implant in a minipig model. SP-26 is aimed at treating chronic pain and fibromyalgia. The study will explore the absorption, distribution, metabolism, and excretion (ADME) of the extended-release ketamine hydrochloride implants over three weeks, testing two polymer formulations at varying doses. The advancement to animal studies marks a significant milestone for Silo in developing a new ketamine treatment for chronic pain. If successful, SP-26 could qualify for the FDA's streamlined 505(b)(2) regulatory pathway.

Silo Pharma Sp 26 Ketamine Chronic Pain Fibromyalgia Pharmacokinetics Biopharmaceutical

Story submitted by Fairstory

RATING

7.8

Fair Story

Consider it well-founded

The article provides a detailed overview of Silo Pharma's latest preclinical study on a novel pain therapeutic. It is clear and informative, though it primarily presents the company's perspective and lacks broader context or independent sources.

Accuracy

The article appears to be factually accurate regarding the details of the study and the company's focus. However, it relies heavily on statements from the company itself, which may not be independently verifiable.

Balance

The article mainly presents the perspective of Silo Pharma and does not include viewpoints from independent experts or competitors. This limits the balance of perspectives.

Clarity

The article is clearly written, with a logical structure and neutral tone. It avoids emotive language and presents information in a straightforward manner.

Source quality

The primary source is Silo Pharma, which is a credible source regarding its own activities. However, the lack of external sources or expert opinions affects the overall source quality.

Transparency

The article includes a forward-looking statement disclaimer, which is a good practice in terms of transparency. It clearly identifies the nature of the study and the company's involvement.